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Abstract
Background and Objectives Linezolid, a oxazolidinone,
was the first in class to be approved for the treatment of
bacterial infections arising from both susceptible and
resistant strains of Gram-positive bacteria. Since overt
exposure of linezolid may precipitate serious toxicity
issues, therapeutic drug monitoring (TDM) may be
required in certain situations, especially in patients who are
prescribed other co-medications.
Methods Using appropriate oral pharmacokinetic data
(single dose and steady state) for linezolid, both maximum
plasma drug concentration (Cmax) versus area under the
plasma concentration–time curve (AUC) and minimum
plasma drug concentration (Cmin) versus AUC relationship
was established by linear regression models. The predic-
tions of the AUC values were performed using published
mean/median Cmax or Cmin data and appropriate regression
lines. The quotient of observed and predicted values ren-
dered fold difference calculation. The mean absolute error
(MAE), root mean square error (RMSE), correlation
coefficient (r), and the goodness of the AUC fold predic-
tion were used to evaluate the two models.
Results The Cmax versus AUC and trough plasma con-
centration (Ctrough) versus AUC models displayed excellent
correlation, with r values of[0.9760. However, linezolid
AUC values were predicted to be within the narrower
boundary of 0.76 to 1.5-fold by a higher percentage by the
Ctrough (78.3 %) versus Cmax model (48.2 %). The Ctrough
model showed superior correlation of predicted versus
observed values and RMSE (r = 0.9031; 28.54 %,
respectively) compared with the Cmax model (r = 0.5824;
61.34 %, respectively).
Conclusions A single time point strategy of using Ctrough
level is possible as a prospective tool to measure the AUC
of linezolid in the patient population.
Key Points
The linear regression model of maximum plasma
drug concentration (Cmax) versus area under the
plasma concentration–time curve (AUC) Cmax and
trough plasma concentration (Ctrough) versus AUC
showed excellent correlation.
Linezolid AUC values were accurately predicted
with the Ctrough model compared with the Cmax
model, with better error predictions.
The single time point Ctrough model can be utilized in
a prospective fashion to measure the AUC of
linezolid in patients.
1 Introduction
Linezolid, belonging to the oxazolidinone class of
antibacterials, was the first in the class to be granted global
approval for treating a variety of infections related to
Gram-positive pathogens [1, 2]. Both oral and intravenous
drug formulations are available to provide convenient
therapy for patients [2]. Linezolid’s mechanism of action is
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unique and suggested to occur via significant inhibition of
the bacterial protein synthesis complex initiation in the
bacterial system via the direct action of linezolid on the
binding site for initiator transfer RNA (t-RNA) [3, 4].
Linezolid significantly inhibits the growth of a variety of
Gram-positive bacterial strains, including staphylococci,
streptococci, and enterococci. Furthermore, it shows
antimicrobial activity against both methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococci (VRE) [5–7]. The hallmark of linezolid’s
antibacterial activity is its persistent and long-acting post-
antibiotic effect, which may render it useful in strains that
are difficult to treat. In addition, this effect may also curb
the development of bacterial resistance to linezolid. Line-
zolid has been found to be an important option in the
treatment of multiple drug-resistant tuberculosis [MDR-
TB] [8]. Linezolid has an excellent minimum inhibitory
concentration (MIC) against Mycobacterium tuberculosis
and several first-line drug-resistant isolates [9–11]. The
same dosing regimen (every 12 h) used to treat patients
with Gram-positive infections has been used to treat
patients with MDR-TB [11–13].
The safety, tolerability, and pharmacokinetics of line-
zolid in humans has been investigated for both intravenous
and oral use [14–16]. It has been shown to be well tolerated
in doses up to 625 mg given intravenously twice daily for
up to 7 days in the clinic and in doses of either 400 mg or
600 mg given orally twice daily for up to 28 days [14–16].
Pharmacokinetic investigation has confirmed complete
bioavailability of oral linezolid; this suggests it can be used
interchangeably permitting oral and intravenous drug
switches during therapy, if necessary. After oral adminis-
tration, linezolid reached peak levels within 1–1.5 h, sug-
gesting relatively rapid absorption of the drug. After
intravenous administration, the peak levels were reached at
the end of the 30-min drug infusion [14, 16]. Both maxi-
mum plasma drug concentration (Cmax) and area under the
plasma concentration–time curve (AUC) values appeared
to increase in a dose-proportional manner after oral or
intravenous routes of administration. Almost two-thirds of
linezolid total clearance was renal; the remaining one-third
was via non-renal routes [14–16]. Regardless of the
administration route, the half-life of linezolid ranged from
5 to 7 h, supporting twice daily dosing of the drug. Drug
accumulation occurred at steady state, albeit numerically
small. A mass balance study showed that approximately
50 % of administered linezolid was recovered in the urine,
and comprised two inactive metabolites; another 35 % of
the dose was represented by the intact parent compound
[14–16].
We were interested in predicting the AUC of linezolid
using a simple and straightforward approach for universal
application. To be rigorous, we assembled published
pharmacokinetic data of linezolid from various studies with
different subject populations to make the dataset very
heterogeneous in nature. However, for the model devel-
opment we used data from a single pharmacokinetic study
that provided a wide spread of the pharmacokinetic
parameters, such as Cmax, trough plasma concentration
(Ctrough), and AUC for modelling purposes.
2 Scope
• To develop relationship using linear regression corre-
lations of Ctrough versus AUC and Cmax versus AUC of
linezolid from a published oral pharmacokinetic study.
• To perform an internal validation to predict the AUC of
linezolid following intravenous dosing from the same
study using both the developed models.
• To perform an external validation for the prediction of
the linezolid AUC following oral and intravenous
administration from scores of other published studies
using the relevant Ctrough and Cmax data.
3 Methods
We searched the National Center for Biotechnology
Information PubMed database for relevant abstracts and
full-length texts pertaining to the pharmacokinetics of
linezolid. The keywords used in the search included line-
zolid, pharmacokinetics, humans, and clinical. The aim of
the present analysis was to seek a relationship between
Ctrough versus AUC and Cmax versus AUC for linezolid
using unweighted linear regression analysis. Once estab-
lished, we then used the appropriate regression lines in the
prediction of AUC values for linezolid.
3.1 Data Source for Model Development
We obtained the mean pharmacokinetic data that provided
Cmax and AUC values for linezolid from published phar-
macokinetic data in healthy subjects [15–49]. The oral
pharmacokinetic data to create the reference model for
linezolid were from a double-blind, placebo-controlled
study with 3:1 randomization of subjects to active relative
or placebo at all dose levels [16]. The goal of the clinical
study was to obtain clinical safety, tolerability, and phar-
macokinetics data for linezolid after single and multiple
oral administration to healthy subjects. In total, three doses
(375, 500, and 625 mg) of linezolid were administered
orally on day 1 (single dose) and from day 2 onwards
(multiple doses). The same oral doses were administered
for another 14.5 days every 12 h. The second study
examined the safety, tolerability, and pharmacokinetics of
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linezolid in healthy subjects following intravenous drug
administration. Two doses (500 and 625 mg) of linezolid
were administered via a 30-min infusion on day 1 (single
dose) and from day 2 (multiple doses) onwards for another
7.5 days; the same intravenous doses were administered
via a 30-min infusion every 12 h [16].
The pharmacokinetic data were gathered after single and
multiple doses following both oral and intravenous
administration of linezolid. The frequency of the blood
samples was adequate to assess linezolid pharmacokinetics
with single and multiple doses regardless of the drug
administration route. The AUC values used for linezolid in
the Cmax regression model represented both AUCinf (sin-
gle-dose study) and AUCtau (multiple-dose study) values.
However, for the Ctrough regression model, AUCtau values
(multiple-dose study) were used. The AUC data for line-
zolid obtained from the intravenous study were used for
internal validation of the two regression models. In addi-
tion, for each pair of observed Cmax versus AUC and
Ctrough versus AUC, four additional data points were gen-
erated via the addition or subtraction of either one or two
standard deviations from the corresponding mean values of
each parameter (i.e., Cmax, Ctrough, and AUC). This pro-
vided a basis for a larger spread of the Cmax, Ctrough, and
AUC data to facilitate the model development. The
incorporation of standard deviation assisted spread of the
parameter values has been documented in the linear
regression analysis of cyclosporine [50].
For the Cmax model, 30 pairs of Cmax and AUC values
for linezolid were used as raw reference data in establish-
ing the regression model (Table 1). For the Ctrough model,
14 pairs of Ctrough and AUC values for linezolid were used
as raw reference data in establishing the regression model
(Table 1). The data spread of Cmax, Ctrough, and AUC for
linezolid were approximately 7.67-fold (4.07–31.23 lg/
ml), approximately 54.57-fold (0.28–15.28 ng/ml), and
16.74-fold (15.7–262.8 lg 9 h/ml), respectively
(Table 1).
3.2 Linear Regression Model
Separate linezolid models representing Cmax versus AUC
and Ctrough versus AUC were established by performing an
un-weighted linear regression of the respective paired
datasets to obtain the regression lines:
Y ¼ mX þ C;
where m is the slope of the line and C is the intercept value.
For each regression model of the paired datasets, a corre-
lation coefficient was established. The developed Cmax
versus AUC model was utilized in the prediction of the
AUC for the linezolid. The in-built statistical package in
Microsoft Excel 2010 (Microsoft Company, Redmond,
WA, USA) was used to perform linear regressions and
establish correlation coefficients.
3.3 Prediction Using Published Cmax and Ctrough
Data
3.3.1 Internal Dataset Validation
The intravenous data obtained from the same study that
supplied the raw reference data for establishing the
regression models using both Cmax and Ctrough were used
for the internal validation [16].
3.3.2 External Dataset Validation
Scores of publications that described the pharmacokinetics
of linezolid after oral and intravenous dosing in a variety of
patient populations and heathy subjects were gathered [15–
49], and the respective observed individual, mean/median
Cmax or Ctrough values were used to predict AUC for line-
zolid using the regression lines as applicable. The predicted
AUC values obtained from the two models were then
subjected for additional statistical tests.
3.4 Statistical Tests and Fold-Difference
Computation
The fold difference of the linezolid AUC prediction was
separately calculated for the two regression models and
was defined as the quotient of observed AUC and pre-
dicted AUC value. Various categories of fold difference
ranging from\0.5-fold, 0.51- to 0.75-fold, 0.76- to 1.25-
fold, 1.26 to 1.5-fold, 1.51 to 2-fold, and [2-fold were
created to understand the spread and goodness of the
prediction.
For the purpose of the current analysis, a prediction
within 0.5 to 2-fold difference was considered satisfactory
for the external dataset validation and a narrower predic-
tion of within 1.5-fold difference was considered appro-
priate for the internal dataset validation. Fold difference-
based statistical comparison has previously been employed
and validated for several drugs [50–56].
We used a double-sided paired t-test to evaluate the
observed (literature data) versus predicted AUC for the
linezolid. The mean absolute error (MAE) was defined as
the mean of the observed AUC values minus the predicted
AUC values of linezolid; 95 % confidence interval limits
were generated and an appropriate p-value was assigned
for the statistical significance using the T-test calculator
(Graphpad, San Diego, CA, USA).
MAE ¼
XN
i¼1
xi yið Þ
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In addition, we calculated mean square error and root
means square error (RMSE) for linezolid (shown below)
using Microsoft Excel 2010.
MSE ¼ 1
N
XN
i¼1
xi yið Þ2
RMSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N
XN
i¼1
xi yið Þ2
vuut
3.5 Data Utility and Conversions
All data points from the reference data, with the exception
of a single pair for the Ctrough model were used in the
model development for linezolid. For consistency for the
data assessment, Cmax values were reported in lg/ml units;
AUC values were reported in lg 9 h/ml. Data unit con-
versions, if necessary, were made as applicable during
compilation and tabulation of the pharmacokinetic data
using the same uniform unit format.
Table 1 Pharmacokinetic data used for developing linear regression models for linezolid
Model
type
Route, dose, type Data
tabulation
Single dose Multiple dose Reference
Cmax
(lg/ml)
AUCinf
(lg 9 h/ml)
Cmax
(lg/ml)
AUCtau
(lg 9 h/ml)
Cmax Oral, 375 mg, single dose Mean 8.21 65.5 13.1 82.8 Stalker et al. [16]
Mean (-1 SD) 6.14 40.6 10.2 60.2
Mean (?1 SD) 10.28 90.4 16 105.4
Mean (-2 SD) 4.07 15.7 7.3 37.6
Mean (?2 SD) 12.35 115.3 18.9 128
Oral, 500 mg, single dose Mean 10.4 74.3 15.3 99.2
Mean (-1 SD) 7.87 46.4 11.58 62.5
Mean (?1 SD) 12.93 102.2 19.02 135.9
Mean (-2 SD) 5.34 19.3 7.86 25.8
Mean (?2 SD) 15.46 130.1 22.74 172.6
Oral, 625 mg, single dose Mean 12.7 102 18.75 147
Mean (-1 SD) 9.34 72.3 12.51 89.1
Mean (?1 SD) 16.06 131.7 24.99 204.9
Mean (-2 SD) 5.98 42.6 6.27 31.2
Mean (?2 SD) 19.42 161.4 31.23 262.8
Ctrough Oral, 375 mg, single dose Mean NA NA 3.9
a 82.8
Mean (-1 SD) 2.05 60.2
Mean (?1 SD) 5.75 105.4
Mean (-2 SD) 0.18b 37.6b
Mean (?2 SD) 7.6 128
Oral, 500 mg, single dose Mean NA NA 5.04 99.2
Mean (-1 SD) 2.66 62.5
Mean (?1 SD) 7.42 135.9
Mean (-2 SD) 0.28 25.8
Mean (?2 SD) 9.8 172.6
Oral, 625 mg, single dose Mean NA NA 8.02 147
Mean (-1 SD) 4.39 89.1
Mean (?1 SD) 11.65 204.9
Mean (-2 SD) 0.76 31.2
Mean (?2 SD) 15.28 262.8
AUC area under the plasma concentration–time curve, Cmax maximum plasma drug concentration, Ctrough trough plasma concentration, NA not
available
a Ctrough reported
b Value excluded from the regression analyses
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4 Results
As illustrated in Fig. 1, the Cmax versus AUC and Ctrough
versus AUC linear regression models were established for
linezolid using the reference data presented in Table 1. An
excellent correlation coefficient (r) value of 0.9762
(p\ 0.001) and 0.9979 (p\ 0.001) were obtained for the
Cmax and Ctrough models, respectively.
The prediction of AUC values for linezolid using the
two models was performed using the regression equations
described below:
AUCðlinezolidÞ ¼ CmaxðlinezolidÞ  8:8282 20:284
AUCðlinezolidÞ ¼ CtroughðlinezolidÞ  15:598 20:557
4.1 Internal Dataset Prediction
As shown in Table 2, the use of either Cmax or Ctrough
regression models developed using oral linezolid data
adequately predicted the AUC values obtained after intra-
venous administration at steady state. The fold difference
in the predicted AUC for linezolid was 0.84 and 1.15, for
Cmax and Ctrough models, respectively.
4.2 External Dataset Prediction
4.2.1 Cmax Model
Figure 2 displays the comparison of the observed AUC
values versus predicted AUC values for linezolid. Less
than 50 % of the predicted AUC values were within the
0.76- to1.5-fold limit of the original values (Table 3).
Furthermore, AUC fold difference was distributed across
the various segments, suggesting a greater variability in the
prediction of AUC (Table 3). For instance, 16.6 % of the
AUC predictions were\0.5-fold difference, and 1.4 % of
the AUC predictions were[2.0-fold difference. The plot of
observed AUC versus predicted AUC values for linezolid
is shown in Fig. 3 and had a correlation of 0.5824, n = 222
(p\ 0.001). The MAE and RMSE (expressed as %) were
21.34 and 61.34 %, respectively (Table 3).
4.2.2 Ctrough Model
Figure 2 displays the comparison of the observed AUC
values versus predicted AUC values for linezolid. More
than 75 % of the predicted AUC values (i.e., 78.3 %) were
within the 0.76- to 1.5-fold limit of the original values
(Table 3). Unlike the Cmax model, no AUC predictions of
linezolid were either\0.5- or[2.0-fold difference, sug-
gesting the containment of the AUC values within 0.5- to
2-fold difference (Table 3). The plot of observed AUC
versus predicted AUC values for linezolid is shown in
Fig. 3 and had a correlation of 0.9031, n = 120
(p\ 0.001). The MAE and RMSE (expressed as percent-
ages) were 16.40 and 28.54 %, respectively (Table 3).
5 Discussion
The increased risk posed by resistant Gram-positive
pathogens causing frequent fatalities can be circumvented
with the prudent use of linezolid to treat a variety of
infections. Linezolid is one of the few antibiotics that
possess excellent pharmacokinetic properties, such as
almost 100 % [14–16] bioavailability and rapid Cmax after
oral administration (almost matching the Cmax obtained
after standard intravenous infusion of the drug), meaning it
is easily possible to switch from intravenous to oral drug
administration regimens. Therefore, transitioning patients
from a hospital/institutional setting to a home setting is
made easy with the possibility of changing an intravenous
prescription of linezolid to an oral regimen with a dose
alteration. This prompted us to establish simple regression
models using oral pharmacokinetic data that would enable
the prediction of AUC data for linezolid using a single time
point strategy regardless of the administration route.
Fig. 1 Linear regression models developed by linezolid Cmax vs.
linezolid AUC and linezolid Ctrough vs. linezolid AUC. AUC area
under the plasma concentration–time curve, Cmax maximum plasma
drug concentration, Ctrough trough plasma concentration
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The AUC of linezolid is a vital parameter, and the ratio
of AUC/MIC has been used as a surrogate for both bac-
teriological and clinical outcomes [14]. Note also that the
linezolid AUC has also been linked to the occurrence of
thrombocytopenia [14].
The reference data for linezolid AUC used for
building either Cmax or Ctrough models represented either
AUCtau (every 12 h dosing schedule) or AUCinf (single-
dose) values. Because linezolid exhibits linear pharma-
cokinetics, steady state exposure was expected to be
comparable to the single-dose AUCinf data. The calcu-
lated AUC values from either of the two models are
representative of the exposure of linezolid in a dosing
interval since the majority of the examples used in the
Table 2 Internal dataset validation: prediction of intravenous area under the plasma concentration–time curve data for linezolid using regression
models from oral data
Model type Route, dose, type Observed Predicted Fold difference Reference
AUCtau (lg 9 h/ml) AUCtau (lg 9 h/ml)
Cmax Intravenous, 500 mg, multiple dose 81.2 106.84 0.76 Stalker et al. [16]
61.6 79.65 0.77
100.8 134.03 0.75
42 52.46 0.80
120.4 161.22 0.75
Intravenous, 625 mg, multiple dose 93.4 118.32 0.79
61.1 95.19 0.64
125.7 141.45 0.89
158 164.58 0.96
Ctrough Intravenous, 500 mg, multiple dose 81.2 75.31 1.08
61.6 54.09 1.14
100.8 96.52 1.04
42 32.88 1.28
120.4 117.73 1.02
Intravenous, 625 mg, multiple dose 93.4 80.45 1.16
61.1 42.08 1.45
125.7 118.82 1.06
158 157.20 1.01
AUC area under the plasma concentration–time curve, Cmax maximum plasma drug concentration, Ctrough trough plasma concentration
Fig. 2 Spread of the observed AUC vs. predicted AUC for either linezolid Cmax model (a) or linezolid Ctrough model. AUC area under the plasma
concentration–time curve, Cmax maximum plasma drug concentration, Ctrough trough plasma concentration
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dataset were from multiple-dose pharmacokinetic studies
of linezolid.
Although we were limited by not having individual
datasets to build the Cmax versus AUC and Ctrough versus
AUC linear regression models, the mean ± standard
deviation approach enabled us to generate additional data
points. While this strategy enabled a wider spread of the
Cmax, Ctrough, and AUC values for linezolid, it did not
compromise the scientific integrity of the analysis. For
instance, the Cmax versus AUC analysis would have yielded
a slope value of 7.3458 using as is data, which was in close
proximity to the value of 8.8282 with additional data
points. Similarly, for the Ctrough versus AUC analysis, the
slope value of 15.6750 (as is data) was almost overlapping
with the slope value of 15.5980 (with additional data
points). The internal validation unequivocally supported
the ability of models developed with oral data to predict the
intravenous exposure data of linezolid, irrespective of Cmax
or Ctrough models.
Based on statistical comparisons, the superiority of
Ctrough over that of Cmax in predicting the AUC of linezolid
was established with[2-fold better error prediction ren-
dered by the Ctrough model (RMSE: 28.54 %) as compared
with the Cmax model (RMSE: 61.34 %). The distribution ofT
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Fig. 3 Correlation of the observed vs. predicted values for either the
linezolid Cmax model or the linezolid Ctrough model. AUC area under
the plasma concentration–time curve, Cmax maximum plasma drug
concentration, Ctrough trough plasma concentration
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AUC fold-differences in the prediction suggested that the
Ctrough model predicted the AUC values to a large extent
within the narrow band of 0.75- to 1.5-fold differences.
This ability of the Ctrough model to consistently predict
linezolid AUC values within a narrower boundary may be
useful in determining the potential for any drug–drug
interaction with other drugs co-administered with linezolid.
For instance, in the drug–drug interaction study of clar-
ithromycin with linezolid [35], the mean observed AUC for
linezolid was 61 (34.6–63.9) ng 9 h/ml and the Ctrough
model predicted AUC values were 53.1 (34.6–54.9)
ng 9 h/ml, which confirmed its utility.
A clinical pharmacokinetic study was performed previ-
ously to explore a limited sampling strategy for the thera-
peutic drug monitoring (TDM) of linezolid in patients with
MDR-TB [34]. Interestingly, the strategy comprised Ctrough
(alone) and Ctrough combined with two to three additional
time points within the 0- to 12-h dosing interval of linezolid.
The use ofCtrough alone was identified as useful for the TDM
of linezolid. Thiswas awell planned and executed studywith
a homogenous patient population, and it yielded an r value of
0.91 and an RMSE of 15 % [34]. To put things into per-
spective, the present analysis of linezolid was heterogeneous
in terms of the nature of studies carried out in different
geographies with applicable clinical protocols and collated
data for over a decade, covering different patient populations
being treated with linezolid for various resistant Gram-pos-
itive pathogens, and it also included oral and intravenous
administration routes. Despite the enormous heterogeneity,
we were able to establish an r value of 0.90 and an RMSE of
29 % using the CtroughCtrough-based model. Furthermore, we
also examined two individual patient studies of linezolid that
had a sample size of at least n = 10 and performed the
regression analysis of Ctrough versus AUC values to further
validate our developed model, which was based on mean
data in healthy subjects.
The first study involved critically ill patients with ven-
tilator-associated pneumonia, where plasma and intrapul-
monary linezolid concentrations were determined [25]—
the Ctrough versus AUC regression analysis yielded:
AUC ðlinezolidÞ ¼ Ctrough ðlinezolidÞ  14:884þ 34:894
ðr ¼ 0:8464Þ:
The second study involved critically ill neurological
patients where both cerebrospinal fluid and serum
concentrations were measured [44]—the Ctrough versus
AUC regression analysis yielded:
AUC ðlinezolidÞ ¼ Ctrough ðlinezolidÞ  16:145þ 38:795
ðr ¼ 0:9771Þ:
Using the examples of the individual patient studies, our
present analysis when put into context with previously
reported limited sampling strategy work on linezolid [34]
strongly suggests that a Ctrough model could be used
prospectively in patients. A single sample collection at
Ctrough has the distinct advantage of minimizing the risk of
other opportunistic infections in a community setting. Also,
the Ctrough model would be beneficial when other
concomitant drugs are administered, since the sample
time is distant from absorption and metabolism processes
that may affect the pharmacokinetics of the drug. Perhaps
the same sample collected for linezolid may also be useful
for measuring other concomitant drugs.
Although we understood that theCmax versus AUCmodel
may not be ideal, we attempted to build the model and val-
idate it further. We believe that since Cmax is largely influ-
enced by the sampling times to define the pharmacokinetic
profile of the drug, it may exhibit more intra- and inter-
subject variability. From a practicality viewpoint, it may be
difficult to sample for a precise Cmax estimation because it
would involve intensive pharmacokinetic sampling. In the
present analysis, Cmax may also have been influenced by
differences in the duration of intravenous infusion of line-
zolid (30 min vs. 1 h infusion). Therefore, institution of a
Cmax-based model as a strategy should be considered after
carefully weighing the number of limitations it imposes.
As published pharmacokinetic data were lacking, we
were unable to examine the predictability of linezolid AUC
in obese subjects using either the Cmax or the Ctrough
models. However, we used the recently published data by
Bhalodi et al. [57] to examine the predictability of the
AUCtau of linezolid using the Cmax model. Using the mean
Cmax (20.9 lg/ml) of linezolid in moderately obese patients
[57], the predicted AUCtau value was 182.4 lg 9 h/ml as
compared with the observed AUCtau of 130.3 lg 9 h/ml.
Similarly, using the mean Cmax (18.8 lg/ml) in morbidly
obese patients [57], the predicted AUCtau was 161.9
lg 9 h/ml as compared with the observed AUCtau of 109.2
lg 9 h/ml. Although Ctrough data were not available in this
study [57], using the Cmax model suggested that the
developed models were applicable for the prediction of
linezolid AUCtau in obese patients.
Our work has additional limitations: first, the linear
regression models, either Cmax or Ctrough, developed for
linezolid were based on mean data but not on individual
subject datasets; second, the AUC predictions for either of
the models were based on mean data, while the prediction
errors may not truly reflect the errors of the population at
large. Third, although the Ctrough model appeared to pro-
vide the best accuracy and bias for predicting AUC values,
the clinical pharmacokinetic data in patients should be
interpreted with utmost caution, keeping in mind
polypharmacy and/or attenuated pathophysiological con-
siderations because of the disease state. Fourth, the Ctrough
model can only be used to render the AUC prediction of
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linezolid in a dosing interval (s = 12 h), but it may be less
than ideal for the prediction of AUCinf following single-
dose administration of linezolid.
6 Conclusions
The Cmax versus AUC and Ctrough versus AUC models were
unambiguously established for linezolid using published
data. The predictions of AUC values using the Ctrough
model were found to be superior to those of the Cmax model
as judged by fold-difference calculations and error pre-
dictions such as MAE and RMSE values and correlation
coefficients. Since excellent predictions of the AUC values
of linezolid were obtained by the Ctrough model, a single
time point strategy of measuring Ctrough level is possible as
a prospective tool in the patient population.
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